Clinical Trial

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 in healthy adult participants (18 to 80 years of age).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-04
Trial Details
NCT Number NCT05992935
Lead Sponsor ModernaTX, Inc.
Conditions Norovirus Acute Gastroenteritis
Enrollment 1,407 participants
Start Date 2023-08-25
Primary Completion 2026-09-22 (estimated)
Study Completion 2026-09-22 (estimated)
Updated on ClinicalTrials.gov 2026-04-03